Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 149, Issue 5, Pages 401-411Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ajcp/aqy003
Keywords
Antiphospholipid; Anticardiolipin; APhL; Antiphosphatidylserine; Antiphosphatidylinositol; Assay; Noncriteria
Categories
Funding
- National Institutes of Health [AR43727, AR69572, AR056745-01A1]
- Mallinckrodt-Questcor Fellowship Grant
Ask authors/readers for more resources
We evaluate the performance characteristics of antiphosphatidylserine (anti-PS), antiphosphatidylinositol (anti-PI), and antiphospholipid mixture (APhL) enzyme-linked immunosorbent assays (ELISAs) compared with anticardiolipin (aCL) and anti-beta 2 glycoprotein I (anti-beta 2GPI) in a large group of patients with antiphospholipid (aPL)-related diseases. Serum samples from 548 patients from the Hopkins and Jamaican systemic lupus erythematosus cohorts, the PROMISSE cohort, and the Antiphospholipid Standardization Laboratory were examined for immunoglobulin G (IgG)/immunoglobulin M (IgM) positivity in aCL, anti-beta 2GPI, anti-PS, anti-PI, and APhL ELISA assays. All IgG assays were associated with one or more thrombotic and/or obstetric manifestations, with an increased risk associated with higher antibody titers. Analytical performance was similar among assays, but IgG assays performed better than IgM counterparts. Increasing titers of APhL, anti-PS, and anti-PI antibodies could indicate an increased risk of thrombotic and/or obstetric aPL-related manifestations. These assays may be promising biomarkers for particular APS manifestations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available